Adding IL-2 to Tebentafusp to Eradicate Cancer Progression — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Adding IL-2 to Tebentafusp to Eradicate Cancer Progression — Stella

Home/Uveal Melanoma/

View on ClinicalTrials.gov

Recruiting

Back to Uveal Melanoma trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(2 sites)

Australia

Kinghorn Cancer Centre, St. Vincent's Hospital, Sydney, New South Wales

Alfred Hospital, Melbourne, Victoria

Key details

Phase

Early testing / Safety & dosing

Sponsor

St Vincent's Hospital, Sydney

Enrollment target

~8 participants

Started

June 2025

Primary completion

September 2027

Age range

18 Years and older

Last updated July 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.